Predict your next investment

Non-Profit Foundation
williamkwarrenfoundation.org

See what CB Insights has to offer

Investments

6

Portfolio Exits

1

About William K. Warren Foundation

William K. Warren Foundation is a private foundation that established Saint Francis Hospital South, Saint Francis Heart Hospital, The Children's Hospital at Saint Francis, and Warren Clinic, which comprise the Saint Francis Health System. The goal of the Foundation has been to provide the finest possible medical care available to all patients utilizing Saint Francis Health System and to this end, it annually supports various medical programs.

William K. Warren Foundation Headquarter Location

Oklahoma,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest William K. Warren Foundation News

Researchers at LIBR identify abnormal heart-brain connection in generalized anxiety disorder

Feb 2, 2022

Researchers at LIBR identify abnormal heart-brain connection in generalized anxiety disorder **EMBARGOED UNTIL 10:00am CT WEDNESDAY, FEBRUARY 2, 2022** Tulsa, Okla. – Researchers at the Laureate Institute for Brain Research (LIBR) in Tulsa, Okla., have identified an abnormal link between the autonomic and central nervous systems, specifically via communication between the heart and part of the brain’s frontal cortex, in women with generalized anxiety disorder (GAD). The team’s objective was to test whether individuals suffering from GAD show dysfunction in the neural circuitry underlying cardiovascular arousal and whether that may be associated with certain disorder-related symptoms such as anxiety and body sensation. To conduct the study, they completed a randomized clinical trial of 58 adult female participants (29 with GAD and 29 matching healthy comparisons). During the study they stimulated the cardiovascular system using a medicine called isoproterenol, which mimics the effects of adrenaline but, unlike adrenaline, cannot cross the blood-brain-barrier to directly impact brain activity. Intravenous infusions of isoproterenol or saline were administered during functional magnetic resonance imaging, allowing them to assess whether the brains of patients with GAD differ in the processing of information received from the body, a function known as ‘interoception’. The main findings were that patients with GAD differed significantly from healthy participants on several variables, but only during the lower of two dosages of isoproterenol. Specifically, they perceived their heartbeats to be more intense and had relatively higher heart rates and lower neural activity in the ventromedial prefrontal cortex, a brain area known to regulate the autonomic nervous system and to facilitate feelings of fear or safety. Self-reported anxiety was significantly higher only for those with GAD compared to healthy participants in response to either dose. The research findings, “Association of Generalized Anxiety Disorder with Autonomic Hypersensitivity and Blunted Ventromedial Prefrontal Cortex Activity During Peripheral Adrenergic Stimulation,” were published in the February 2, 2022 edition of JAMA Psychiatry. For lead author Adam Teed, a postdoctoral associate at LIBR, the fact that the abnormal results observed for those with GAD occurred during lower, but not higher, doses of medicine was the primary finding from the study: “administering isoproterenol allowed us to provide causal evidence that an abnormally sensitive cardiovascular system and an abnormally insensitive frontal cortex in GAD patients lowers their ability to regulate bodily arousal. This could help to explain why they experience anxiety so frequently and in a wide variety of contexts.” The authors hope that their study prompts further research into the ventromedial prefrontal cortex as a therapeutic target for novel treatments helping individuals with GAD to regulate physiological and emotional responses to stress. Beyond the novel link revealed by this study, it is noteworthy that cardiovascular hypersensitivity was observed for GAD patients at all. This is because the Diagnostic and Statistical Manual of Mental Disorders (DSM–5), the standard classification system used by mental health professionals in the United States, describes autonomic symptoms such as sweating, rapid heart rate, or shortness of breath, as being less prominent in GAD than other anxiety disorders, such as panic disorder. As senior author Sahib Khalsa, MD, PhD, a psychiatrist and principal investigator at LIBR puts it, “this study shows us that anxiety is not only something that happens within our brains but within our bodies as well.” Thus, these findings show that abnormal functioning of the autonomic nervous system is not only a factor in GAD, but it occurs in combination with abnormal functioning of certain areas of the brain. Such associations are what Dr. Khalsa believes to be the most important product of this research: “it is the interaction between our brain and body that may be essential for determining whether an innocuous situation creates a state of fear in individuals with GAD. We need to better understand how this abnormal physiological response relates to the functional impairments that commonly interfere with the daily lives of such individuals.” The research team was led by senior author Sahib Khalsa, MD, PhD, also an associate professor in the Oxley College of Health Sciences at The University of Tulsa, and lead author Adam Teed, PhD, and included others from LIBR as well as The University of Oklahoma (OU), the University of California at Los Angeles (UCLA), and the University of California at San Diego (UCSD). The research was supported by the National Institute of Mental Health, The William K. Warren Foundation, and the National Institute of General Medicine Sciences and was conducted at LIBR between January 2017 and November 2019. # # # ABOUT LAUREATE INSTITUTE FOR BRAIN RESEARCH (LIBR) Launched in 2009, the Laureate Institute for Brain Research (laureateinstitute.org) is home to a multidisciplinary team of scientists and clinical research staff who apply neuroimaging, generic, pharmacological and neuropsychological tools to investigate the biology of neuropsychiatric disorders. LIBR’s creation was supported by The William K. Warren Foundation for the purpose of conducting studies aimed at developing more effective treatments and/or prevention strategies for these disorders. The studies are led by scientists from diverse backgrounds, including physics, cognitive neuroscience, psychology, psychiatry, neurology, developmental neuroscience, computer science, and genetics Journal

William K. Warren Foundation Investments

6 Investments

William K. Warren Foundation has made 6 investments. Their latest investment was in Spring Health as part of their Series C on September 9, 2021.

CBI Logo

William K. Warren Foundation Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/16/2021

Series C

Spring Health

$150M

No

4

11/18/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

1/24/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

6/6/2018

Seed VC - IV

Subscribe to see more

$99M

Subscribe to see more

10

12/19/2017

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/16/2021

11/18/2020

1/24/2020

6/6/2018

12/19/2017

Round

Series C

Series B

Series A

Seed VC - IV

Series A

Company

Spring Health

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$150M

$99M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

10

10

10

10

William K. Warren Foundation Portfolio Exits

1 Portfolio Exit

William K. Warren Foundation has 1 portfolio exit. Their latest portfolio exit was iRecommend on January 24, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/24/2021

Acquired

$99M

1

Date

1/24/2021

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

1

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.